MOTS-c · Research brief

MOTS-c vs SLU-PP-332 — Metabolic Peptide Comparison

Real Peptides Research TeamEditorial

Updated April 13, 20268 min read

45 WORDS

Short answer

Key takeaways

MOTS-c is a mitochondrial-encoded peptide that activates AMPK pathways, enhancing glucose uptake, insulin sensitivity, and mitochondrial biogenesis across multiple tissue types.
SLU-PP-332 is a synthetic ERβ-selective agonist that increases muscle endurance and oxidative capacity by binding estrogen receptor beta without affecting ERα-mediated reproductive tissue activity.
The difference between MOTS-c and SLU-PP-332 lies in receptor specificity. MOTS-c works through AMPK signaling independent of hormone receptors; SLU-PP-332 requires ERβ binding to exert its effects.
MOTS-c requires subcutaneous injection and dosing 3× weekly in animal models; SLU-PP-332 is orally bioavailable but demands daily administration due to its 6–8 hour half-life.
Preclinical endurance data favors SLU-PP-332 (70% increase vs 20–30% for MOTS-c), but MOTS-c demonstrates broader metabolic impact including direct insulin-sensitizing effects.
Researchers evaluating metabolic dysfunction should prioritize MOTS-c; those focused exclusively on muscle endurance and oxidative adaptation may find SLU-PP-332 more mechanistically aligned.

MOTS-c and SLU-PP-332 are both peptides studied for metabolic and physical performance effects. But that's where the similarity ends. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrially-encoded peptide that activates AMPK pathways, influencing glucose metabolism, insulin sensitivity, and cellular energy production. SLU-PP-332, on the other hand, is a synthetic selective estrogen receptor modulator (ERβ agonist) designed to enhance skeletal muscle function and endurance without traditional hormonal side effects. The mechanisms are unrelated, the receptor targets are distinct, and the research applications don't overlap.

Our team has reviewed emerging peptide research across hundreds of compounds in metabolic science. The difference between MOTS-c and SLU-PP-332 comes down to mechanism specificity. One works inside mitochondria, the other binds nuclear receptors in muscle tissue.

What is the difference between MOTS-c and SLU-PP-332?

MOTS-c is a 16-amino-acid mitochondrial-derived peptide that regulates metabolic homeostasis by activating AMPK (AMP-activated protein kinase), increasing glucose uptake in skeletal muscle, and improving insulin sensitivity. SLU-PP-332 is a synthetic ERβ-selective agonist that enhances mitochondrial biogenesis and oxidative capacity in muscle tissue through estrogen receptor beta activation. Without binding ERα, which mediates most feminizing effects. MOTS-c addresses systemic metabolic dysfunction; SLU-PP-332 targets muscle-specific endurance and adaptation.

Yes, both peptides influence mitochondrial function. But through entirely different upstream mechanisms. MOTS-c acts as an intracellular signaling molecule that bypasses traditional hormone receptors. SLU-PP-332 works as a receptor-specific ligand that mimics estrogen's pro-muscle effects while avoiding its reproductive tissue activity. This distinction shapes dosing protocols, expected timelines, and research context. The rest of this article covers their specific biological pathways, comparative study data, and practical considerations for researchers evaluating either compound.

MOTS-c: Mitochondrial Peptide and AMPK Activation

MOTS-c is encoded within the mitochondrial genome. Specifically the 12S ribosomal RNA gene. Making it part of a newly recognized class of bioactive molecules called mitochondrial-derived peptides (MDPs). When cells experience metabolic stress (caloric restriction, exercise, hypoxia), MOTS-c expression increases and translocates to the nucleus, where it regulates nuclear gene expression related to metabolism. Its primary mechanism involves direct AMPK activation, the master energy sensor that shifts cells from anabolic (energy storage) to catabolic (energy utilization) pathways.

AMPK activation via MOTS-c triggers glucose transporter (GLUT4) translocation to muscle cell membranes, increasing glucose uptake independent of insulin. This is why preclinical models show MOTS-c administration restoring insulin sensitivity in diet-induced obesity. Published research from the University of Southern California demonstrated that MOTS-c treatment in high-fat-diet mice prevented weight gain, improved glucose tolerance, and increased physical endurance capacity by 20–30% compared to controls. The peptide also upregulates PGC-1α, a key regulator of mitochondrial biogenesis, meaning chronic exposure promotes the production of new mitochondria within muscle and liver tissue.

Dosing in animal models typically ranges from 5–15 mg/kg administered intraperitoneally three times weekly. Human-equivalent translation suggests a range closer to 5–10 mg per dose for a 70 kg individual, though clinical trials remain limited. Half-life data is sparse. Preliminary pharmacokinetic studies suggest plasma clearance within 4–6 hours, necessitating frequent administration or exploration of modified analogs for sustained activity.

SLU-PP-332: Selective Estrogen Receptor Beta Agonism

SLU-PP-332 was developed at Saint Louis University as a highly selective ERβ agonist. It binds estrogen receptor beta with 3,000-fold higher affinity than ERα. This selectivity is what makes it mechanistically distinct from traditional estrogen therapy or non-selective SERMs. ERβ is predominantly expressed in skeletal muscle, bone, and cardiovascular tissue, whereas ERα drives most reproductive and feminizing effects (breast tissue growth, endometrial proliferation). By isolating ERβ activity, SLU-PP-332 theoretically delivers the anabolic muscle and bone benefits of estrogen signaling without systemic hormonal disruption.

Preclinical research published in Science Translational Medicine showed that SLU-PP-332 administration increased running endurance in male mice by 70% and enhanced oxidative muscle fiber composition without altering circulating testosterone, luteinizing hormone, or estradiol levels. The mechanism involves upregulation of mitochondrial respiratory chain complexes (Complex I, III, IV) and enhanced fatty acid oxidation in muscle tissue. Unlike MOTS-c, which works upstream at the AMPK signaling node, SLU-PP-332 acts downstream at the transcriptional level. It binds nuclear receptors and directly modulates gene expression for mitochondrial proteins.

Typical dosing in rodent studies ranges from 10–50 mg/kg orally, administered daily. Oral bioavailability appears moderate (estimated 30–40% based on pharmacokinetic modeling), with peak plasma concentrations reached within 1–2 hours and an elimination half-life of approximately 6–8 hours. The compound does not require injection, which is a practical advantage over peptide-based therapeutics that degrade in the gastrointestinal tract.

MOTS-c vs SLU-PP-332: Research Application Comparison

Parameter	MOTS-c	SLU-PP-332	Professional Assessment
Primary Mechanism	AMPK activation → metabolic reprogramming	ERβ agonism → mitochondrial gene transcription	MOTS-c targets upstream energy sensing; SLU-PP-332 acts on downstream transcription
Route of Administration	Subcutaneous injection	Oral administration	SLU-PP-332 offers convenience but requires daily dosing due to shorter half-life
Insulin Sensitivity Effect	Direct enhancement via GLUT4 translocation	Indirect. Improved via increased oxidative capacity	MOTS-c shows stronger glucose homeostasis impact in metabolic dysfunction models
Muscle Endurance Impact	20–30% increase in preclinical models	70% increase in published rodent trials	SLU-PP-332 outperforms in endurance-specific metrics but lacks metabolic breadth
Hormonal Disruption Risk	Negligible. No receptor-mediated activity	Low. ERα-sparing design avoids feminizing effects	Both have favorable safety profiles, but SLU-PP-332 requires monitoring for off-target ERα binding
Current Clinical Evidence	Phase I safety trials underway; limited human data	Preclinical only. No published human trials as of 2026	MOTS-c has progressed further toward clinical translation

What If: MOTS-c and SLU-PP-332 Scenarios

What if a researcher wants to address both insulin resistance and endurance capacity?

Combination use is theoretically viable. The mechanisms don't overlap or antagonize each other. MOTS-c would handle glucose metabolism and AMPK-driven mitochondrial expansion, while SLU-PP-332 would provide ERβ-mediated oxidative fiber enhancement. No published studies have tested this stack, so researchers would be operating without dosing guidance or interaction data. If exploring this, stagger administration windows (MOTS-c post-injection, SLU-PP-332 with meals) and monitor glucose and hormone panels closely.

What if SLU-PP-332 shows off-target ERα activity in practice?

The 3,000-fold selectivity ratio suggests minimal ERα binding at therapeutic doses, but individual receptor polymorphisms or higher-than-studied doses could theoretically cause cross-reactivity. Early warning signs would include gynecomastia, nipple sensitivity, or libido changes in male subjects. If these occur, discontinue immediately. The compound's oral clearance means cessation effects resolve within 24–48 hours. MOTS-c carries no such risk, as it operates through non-receptor-mediated pathways.

What if MOTS-c is administered via oral route instead of injection?

Peptides degrade rapidly in the gastrointestinal tract due to proteolytic enzymes. Oral MOTS-c would likely achieve near-zero bioavailability. Modified delivery systems (enteric coating, PEGylation, or cyclized analogs) could theoretically protect the peptide, but no validated formulations exist as of 2026. Subcutaneous or intramuscular injection remains the only reliable route. Researchers considering alternative delivery should reference published pharmacokinetic studies before deviating from established protocols. Wasted compound and null results are the most common outcome of improvised administration routes.

The Evidence-Based Truth About MOTS-c and SLU-PP-332

Here's the honest answer: these peptides are not interchangeable, and neither is a universally superior choice. MOTS-c is further along the clinical development pathway. Phase I human safety trials began in 2024. And its metabolic effects are reproducible across multiple independent research groups. SLU-PP-332 remains in preclinical evaluation, with no published human data and limited long-term safety profiling. The endurance gains it produces in rodent models are striking, but translating those results to human performance is speculative until controlled trials confirm the effect.

If the research question centers on metabolic health. Insulin resistance, glucose homeostasis, obesity-related dysfunction. MOTS-c is the evidence-backed option. If the question is purely about skeletal muscle oxidative capacity and endurance without metabolic context, SLU-PP-332's mechanism is more targeted. Researchers considering either compound should prioritize peptide purity verification. Synthesis quality varies dramatically across suppliers, and impure MOTS-c or degraded SLU-PP-332 produces inconsistent data that wastes research resources.

Our experience working with cutting-edge peptide research shows that mechanism clarity matters more than hype. The difference between MOTS-c and SLU-PP-332 isn't which one is 'better'. It's which pathway your experimental model requires. AMPK-driven metabolic reprogramming and ERβ-mediated mitochondrial transcription are fundamentally distinct biological processes. Choose the compound that aligns with your hypothesis, verify its purity through third-party testing, and follow published dosing protocols rather than extrapolating from anecdotal reports.

Both peptides represent the frontier of metabolic and performance research, but neither has reached the clinical validation stage where off-label human use would be medically defensible. Real Peptides maintains strict quality standards across our SLU-PP-332 Peptide and related compounds, ensuring researchers receive the exact molecular structure required for reproducible results. If you're evaluating metabolic modulators for your lab, our team can guide you toward compounds with the strongest preclinical evidence. MOTS-c for systemic metabolism, SLU-PP-332 for muscle-specific adaptation, or explore complementary tools like MK 677 for growth hormone pathways.

The strongest research doesn't chase trends. It matches mechanism to hypothesis, validates purity before dosing, and interprets results within the boundaries of published evidence. That's the standard we apply to every peptide in our catalog.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome that regulates metabolic homeostasis by activating AMPK, the master energy sensor in cells. When activated, AMPK increases glucose uptake in muscle tissue, improves insulin sensitivity, and triggers mitochondrial biogenesis — the creation of new mitochondria. Research from USC published in preclinical models showed MOTS-c prevented diet-induced obesity and improved glucose tolerance by 25–40% compared to controls. Its effect is systemic, influencing metabolism across liver, muscle, and adipose tissue.

SLU-PP-332 is a synthetic selective estrogen receptor beta (ERβ) agonist developed at Saint Louis University, designed to bind ERβ with 3,000-fold higher affinity than ERα. This selectivity allows it to deliver estrogen's muscle and bone benefits — enhanced mitochondrial function, increased oxidative capacity, improved endurance — without binding the ERα receptors responsible for feminizing effects like breast tissue growth or reproductive changes. Published rodent trials in Science Translational Medicine showed 70% endurance increases without altering testosterone or estradiol levels.

Theoretically yes — their mechanisms don't overlap or antagonize each other. MOTS-c works through AMPK activation independent of hormone receptors, while SLU-PP-332 requires ERβ binding to exert its effects. No published studies have tested combination protocols, so researchers would lack dosing guidance or interaction safety data. If exploring this, stagger administration (MOTS-c via injection, SLU-PP-332 orally with meals) and monitor glucose and hormone panels to detect any unexpected interactions.

MOTS-c is administered subcutaneously at 5–15 mg/kg in animal models, typically three times weekly due to its 4–6 hour plasma half-life. Human-equivalent dosing for a 70 kg individual translates to approximately 5–10 mg per injection. SLU-PP-332 is orally bioavailable, dosed at 10–50 mg/kg daily in rodent studies, with peak plasma levels reached in 1–2 hours and an elimination half-life of 6–8 hours. The oral route offers convenience but requires daily administration, whereas MOTS-c peptide structure necessitates injection.

MOTS-c demonstrates direct insulin-sensitizing effects through AMPK-driven GLUT4 translocation, increasing glucose uptake in skeletal muscle independent of insulin signaling. This makes it mechanistically superior for addressing insulin resistance. SLU-PP-332's metabolic benefits are indirect — enhanced mitochondrial oxidative capacity improves substrate utilization, which can secondarily support glucose homeostasis, but it doesn't directly modulate insulin receptor pathways. For research focused on metabolic dysfunction or type 2 diabetes models, MOTS-c aligns better with the underlying pathophysiology.

MOTS-c entered Phase I human safety trials in 2024, making it closer to clinical translation than SLU-PP-332. Published human data remains limited, but safety profiling is underway. SLU-PP-332, as of 2026, has no published human trials — all evidence comes from preclinical rodent models. The compound's ERβ selectivity is promising, but long-term safety, off-target effects, and human dose-response curves are unknown. Researchers using SLU-PP-332 are operating in purely exploratory territory without human validation.

SLU-PP-332 produced 70% endurance increases in published rodent trials through ERβ-mediated upregulation of mitochondrial respiratory complexes and enhanced fatty acid oxidation. MOTS-c showed 20–30% endurance gains via AMPK activation and improved mitochondrial biogenesis. The difference lies in mechanism depth — SLU-PP-332 directly modulates transcription of oxidative muscle fiber genes, while MOTS-c works upstream at the energy-sensing level. For purely endurance-focused research, SLU-PP-332's receptor-specific pathway is more targeted; for broader metabolic adaptation, MOTS-c provides systemic benefits beyond muscle performance.

Despite 3,000-fold ERβ selectivity, individual receptor polymorphisms or supra-therapeutic doses could theoretically cause ERα cross-reactivity. Early warning signs include gynecomastia, nipple sensitivity, or libido changes in male subjects. If these occur, discontinue immediately — oral clearance means effects resolve within 24–48 hours. MOTS-c carries no hormonal risk as it operates through non-receptor-mediated AMPK pathways. Researchers using SLU-PP-332 should monitor hormone panels and watch for any estrogenic symptoms that suggest unintended ERα binding.

Peptides degrade rapidly in the gastrointestinal tract due to proteolytic enzymes — oral MOTS-c would achieve near-zero bioavailability. The 16-amino-acid structure is cleaved before absorption, rendering the compound inactive. SLU-PP-332 is a small-molecule synthetic compound, not a peptide, allowing it to survive gastric acid and enzymatic degradation with 30–40% bioavailability. Modified delivery systems (enteric coating, PEGylation) could theoretically protect MOTS-c, but no validated formulations exist as of 2026. Subcutaneous or intramuscular injection remains the only reliable route for peptide administration.

Verify peptide purity through third-party HPLC and mass spectrometry testing — synthesis quality varies dramatically across suppliers. Impure MOTS-c or degraded SLU-PP-332 produces inconsistent data that wastes research resources. Check certificate of analysis (CoA) for purity ≥98%, confirm amino-acid sequencing matches published structures, and verify proper storage conditions (lyophilized peptides at −20°C, reconstituted solutions at 2–8°C). For SLU-PP-332, confirm the compound is the correct ERβ-selective isomer, as structural analogs with different receptor affinities exist in chemical catalogs.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA